Vascular calcification (VC) is a significant risk factor for cardiovascular diseases, often associated with inflammation and oxidative stress. Recent research investigates how canagliflozin, a medication primarily used for diabetes, might offer protective effects against VC by activating cellular autophagy through the AMPK pathway.
This explainer summarizes emerging scientific insights into the mechanisms by which canagliflozin could potentially mitigate vascular calcification, emphasizing its relevance for cardiovascular health management.